Prognostic importance of specific immunoreactivity in occupational bladder cancer

S KUMAR, G TAYLOR, P WILSON, WENDY HURST

Summary and conclusions

Sixty-eight workers with a history of exposure to a bladder carcinogen were followed up to see whether changes in lymphocyte immunoreactivity to a bladder-cancer-cell target were predictive of the development of neoplasia of the urothelium. A twofold or greater increase in reactivity was strongly associated with the development of abnormal urinary cytology suggestive or indicative of malignant change. Changes in immunoreactivity to a non-bladder-cancer-cell target did not have this association.

The findings support the possibility that changes in lymphocyte immunoreactivity may be used to predict the onset of bladder cancer in people exposed to bladder carcinogens.

Introduction

In an earlier study we compared lymphocyte reactivity against a bladder-cancer target cell in a group of workers exposed to bladder carcinogens with that in normal people and patients with bladder cancer. Equivalent increases in reactivity were found in clinically normal carcinogen-exposed workers and patients with bladder cancer when compared with the normal controls. The augmented reactivity was considered to be specific for bladder cancer, as differences in group reactivity against a non-bladder-cancer tumour cell were not found. Furthermore, increases in reactivity in the worker group were related to the degree of exposure to bladder carcinogens and also to the development of abnormal urinary cytology suggestive of early malignant change in the urothelium. We have now followed up the worker group to see whether serial changes in lymphocyte reactivity with time help to predict the development of bladder cancer in individual workers.

Subjects and methods

Chemical workers—Of the original group of 93 workers, 68 were available for continued study. All had been exposed to either 2-naphthylamine, containing 4-8% β-naphthylamine or "pure" β-naphthylamine before 1952. Urinary cytology with Papanicolaou staining was carried out six-monthly and blood samples for lymphocyte toxicity studies taken at about yearly intervals over four years.

Target and effector cells—The bladder-cancer cell (FB) and control target cell (osteosarcoma) were the same as used in our earlier study. They were available stored in liquid nitrogen in aliquots of 1 ml containing about 3 x 10^5 cells in medium 199 with 30% fetal calf serum and 10% dimethyl sulphoxide. To avoid the possibility of antigenic change we did not pass cells during the study. Effector lymphocytes were prepared from 20 ml defibrinated venous blood by the method of Coulson and Chalmers with a phagocyte-removal step using carbonyl iron powder and magnetic separation. The cells were washed three times in Hank's balanced salt solution containing 5% fetal calf serum. Microcytotoxicity tests—We used two procedures for testing microcytotoxicity. The first was based on the method of Takasugi and Klein as modified by Taylor et al. The second method used Se-selenomethionine incorporation to measure residual cells, as described by Brooks et al. With each method five lymphocyte:target-cell ratios were set up, each in replicates of eight. The ratio of lymphocytes to

University Department of Bacteriology and Virology, Manchester

S KUMAR, MEDIC, PhD, (head of paediatric oncology laboratory, Christie Hospital and Holt Radium Institute, Withington, Manchester M20 9BX)
P WILSON, PhD, postdoctoral fellow
WENDY HURST, BSc, postgraduate student

Appalachian Laboratory for Occupational Safety and Health, Morgantown, West Virginia 26508, USA

G TAYLOR, MD, (present address: Wasau Medical Centre, Wasau, Wisconsin 54401, USA)
target cells needed to produce a 50% reduction in target cells as compared with media-only controls (LD$_{50}$) was calculated with the least-squares method of determining residual target cells showed excellent agreement. During the period of study eight workers developed abnormal urinary cytology, as defined by a change to grade III, IV, or V on Papnicolau staining. Changes in LD$_{50}$ against bladder-cancer-cell FB and LD$_{50}$ against the osteogenic sarcoma cell are shown in Table I for these workers and for those who remained in grade I or II during the study. A statistically significant increase in lymphocyte reactivity, as indicated by a rising LD$_{50}$ and LD$_{50}$ occurred against the bladder-cancer-cell target in those workers who developed abnormal urinary cytology as compared with their fellow workers. Changes in reactivity to the osteosarcoma cell were often observed but did not differ significantly in the two groups, both having a median value of no change. In the group with abnormal urinary cytology only one worker showed an increase in reactivity to the osteosarcoma target, whereas seven of the eight had increases in reactivity to the bladder-cancer cell. Table II shows the individual changes in reactivity to the bladder-cancer cell.

**Discussion**

In our earlier study we showed that increased immunoreactivity against a bladder-cancer target cell was associated with factors that are known epidemiologically to predict increased risk of developing bladder cancer. Thus increased immunoreactivity was highest in workers most heavily exposed to known bladder carcinogens. We suggested that measuring immunoreactivity to bladder-cancer cells might provide a means of identifying a very-high-risk group of workers among the high-risk group and that follow-up studies would show if the method could be used for surveillance of individual workers. The results of follow-up showed a strong association between an increase in reactivity towards bladder-cancer target cells on repeated testing and the development of abnormal urinary cytology suggestive or indicative of malignant change in the urothelium. An association was not found between the development of abnormal urinary cytology and changes in immunoreactivity against a non-bladder-cancer target cell, suggesting that the changes in reactivity observed were tumour-specific.

We used an arbitrary criterion of a doubling of reactivity to analyse the results in individual workers. This degree of change occurred in 13 out of 68 workers. Of these, 6 (46%) had developed abnormal urinary cytology while only two out of 55 workers who did not show increases in reactivity of twice or greater had abnormal cytology. Both workers had such low LD$_{50}$ ratios when first measured that it was very unlikely that we could detect an increase of this magnitude when retested. One remained static at this low ratio and the other decreased to the lowest ratio we could detect without reaching the factor of two. Because of the close association between individual workers we are paying close attention to follow-up of the seven currently with normal urinary cytology who showed increases in reactivity. Conversely, maintenance of a relatively static immunoreactivity to bladder-cancer targets apparently carried a good prognosis, at least over the relatively short period of our study. If the two workers with very low LD$_{50}$ ratios on first testing are excluded then no worker in this group developed abnormal cytology. The findings tend to confirm our suggestion that immunoreactivity may be used for surveillance; however, follow-up over much longer than four years will be required to prove its utility.

This study was supported through National Bladder Cancer Project by National Cancer Institute Grant. We thank Drs J Gardiner, W Taylor, G H Shaw and Alyn Evans, medical departments of organics division,ICI Ltd.

**ADDENDUM**—Since submitting the manuscript, we have detected doublings of lymphocytotoxicity in four of a further 16 chemical workers with currently normal urine cytology. These four like the other seven (table II) will need close attention and follow-up.

**References**


(Accepted 23 August 1979)